Alnylam Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biopharmaceutical company built around RNA interference therapeutics. Recent Form 8-K reports furnish operating results and financial condition updates tied to product revenues from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, while other current reports disclose strategy updates, pipeline goals and clinical-program context.
The filing record also covers governance and capital structure matters, including the definitive proxy statement, executive compensation and equity-award disclosures, common stock registered on Nasdaq, a revolving credit facility and convertible senior note offering materials. These disclosures describe board oversight, compensation plans, financing arrangements, material corporate events and the formal exhibits supporting Alnylam's public-company reporting.
ALNYLAM PHARMACEUTICALS director Amy W. Schulman exercised stock options to acquire 11,250 shares of common stock at $70.20 per share. These options were due to expire on June 3, 2026, and the exercise occurred on May 13, 2026. Following the transaction, she directly holds 23,211 common shares. The corresponding stock option position for these 11,250 shares has been fully exercised, with no remaining options from this grant shown in the filing.
Capital World Investors reports beneficial ownership of 10,916,799 shares (8.2%) of Alnylam Pharmaceuticals. The filing states CWI has sole voting power over 10,871,837 shares and sole dispositive power over 10,916,799 shares of the 132,623,144 shares believed outstanding as of the filing. The amendment is signed by a CRMC officer.
Alnylam Pharmaceuticals reports a Schedule 13G/A filing showing Capital Research Global Investors holds 9,471,181 shares of common stock. The filing states this represents 7.1% of 132,623,144 shares outstanding. The filing lists 9,455,765 shares with sole voting power and 9,471,181 with sole dispositive power.
FMR LLC amended its Schedule 13G to report beneficial ownership of 14,640,524.87 shares of PHARMACEUTICALS INC common stock, representing 11.0% of the class as of 03/31/2026. The filing lists 14,103,896.98 shares with sole voting power and states ownership is held on behalf of multiple clients.
Alnylam Pharmaceuticals reported a strong turnaround for the quarter ended March 31, 2026. Total revenues rose to $1,167,175,000 from $594,189,000 a year earlier, driven mainly by net product revenues of $1,036,127,000, with AMVUTTRA contributing $889,931,000.
The company moved from a net loss of $18,251,000 to net income of $205,991,000, or $1.51 per diluted share, as higher sales outpaced increased research and development and selling, general and administrative expenses. Operating income rose to $268,636,000 from $18,077,000.
Alnylam ended the quarter with cash, cash equivalents and marketable debt securities totaling about $3.01 billion and total assets of $5,129,547,000. Stockholders’ equity increased to $1,075,380,000, while the company continued to carry convertible debt and significant liabilities related to the sale of future royalties and development funding.
Alnylam Pharmaceuticals reported a very strong first quarter of 2026, driven by its transthyretin (TTR) franchise. Total revenues nearly doubled to $1.17 billion, with net product revenues of $1.04 billion, up 121% from the same quarter in 2025.
The company swung from a GAAP net loss of $18.3 million in Q1 2025 to GAAP net income of $206.0 million, and non‑GAAP net income rose to $273.0 million. AMVUTTRA generated $889.9 million in sales, and total TTR net product revenues reached $910.4 million, a 153% increase. Rare disease products GIVLAARI and OXLUMO added $125.7 million, up 15%.
Alnylam reiterated its full‑year 2026 guidance, including total net product revenues of $4.9–$5.3 billion and non‑GAAP R&D and SG&A expenses of $2.7–$2.8 billion, while highlighting broad pipeline progress and upcoming clinical readouts in the second half of 2026.
Vanguard Capital Management reported beneficial ownership of 7,104,536 shares of Alnylam Pharmaceuticals common stock, representing 5.35% of the class as of 03/31/2026. The filing shows Vanguard has sole dispositive power over 7,104,536 shares and sole voting power for 1,157,830 shares. The filing is signed by Ashley Grim on 04/29/2026.
Alnylam Pharmaceuticals’ Chief Human Resources Officer Melissa McLaughlin reported routine share sales tied to equity compensation taxes.
The Form 4 shows a total sale of 3,910 shares of common stock on April 2 and 6, 2026, executed automatically under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding on vested restricted stock units. After these transactions, she holds 9,443 shares directly. The filing notes the sales were made under a pre-arranged Rule 10b5-1(c) trading plan adopted on December 16, 2025, indicating they were scheduled in advance rather than opportunistic trades.
Alnylam Pharmaceuticals executive Melissa McLaughlin, Chief Human Resources Officer, reported her equity holdings in the company. She directly holds 13,353 shares of common stock, including restricted stock units that will convert into shares over time.
She also holds a stock option covering 3,567 shares of common stock at an exercise price of $325.07 per share, expiring on March 2, 2036. The option and RSUs vest over multi‑year schedules tied to her continued service.